GPHN and Alzheimer disease: Total levels of GPHN immunoreactivity are reported to decrease with increasing pathology in the AD brain49 and there is evidence for a transcriptional decoupling between GABAAR subunits and GPHN12, two effects that would be consistent with inhibitory deficits in AD.